Anthem (NASDAQ:ANTX) Shares Climb 5.6% – Time to Buy?

Posted by George Bondi on Oct 21st, 2026

Anthem, Inc. (NASDAQ:ANTX – Get Free Report) shares traded up 5.6% during trading on Tuesday. The stock traded as high as $3.59 and last traded at $3.56. 129,744 shares were traded during mid-day trading, a decline of 61% from the average daily volume of 328,782 shares. The stock had previously closed at $3.37.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on ANTX shares. Guggenheim assumed coverage on Anthem in a research note on Monday, July 20th. They set a “buy” rating and a $9.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Anthem in a research report on Friday, October 2nd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Anthem has an average rating of “Hold” and an average price target of $9.00.

Read Our Latest Research Report on Anthem

Anthem Trading Up 5.6%

The company has a market capitalization of $134.35 million, a PE ratio of -3.33 and a beta of -0.98. The stock’s 50-day moving average is $5.21 and its two-hundred day moving average is $4.77.

Anthem (NASDAQ:ANTX – Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter.

Insider Activity

In related news, Director Robin Shane Readnour sold 10,019 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $6.02, for a total transaction of $60,314.38. Following the completion of the sale, the director directly owned 557,990 shares of the company’s stock, valued at approximately $3,359,099.80. This trade represents a 1.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders sold 52,901 shares of company stock worth $318,282. 22.61% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Anthem

Several hedge funds have recently bought and sold shares of the business. Seven Fleet Capital Management LP grew its position in Anthem by 4.6% in the 2nd quarter. Seven Fleet Capital Management LP now owns 208,946 shares of the company’s stock valued at $1,011,000 after acquiring an additional 9,245 shares during the last quarter. Velan Capital Investment Management LP purchased a new stake in Anthem in the second quarter worth $194,000. Citizens Financial Group Inc. RI bought a new stake in shares of Anthem during the second quarter worth $1,443,000. Vivo Capital LLC bought a new stake in shares of Anthem during the first quarter worth $10,785,000. Finally, Bank of America Corp DE lifted its position in shares of Anthem by 2.2% during the first quarter. Bank of America Corp DE now owns 393,702 shares of the company’s stock worth $1,346,000 after purchasing an additional 8,390 shares during the last quarter. Institutional investors own 90.47% of the company’s stock.

Anthem Company Profile

(Get Free Report)

Anthem, Inc is not currently associated with the Nasdaq ticker ANTX. The former Anthem, Inc changed its name to Elevance Health, Inc in 2022 and trades under the ticker ELV. ANTX is the ticker for AN2 Therapeutics, Inc, a separate biotechnology company.

AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for infectious diseases, particularly conditions for which existing therapies are limited. Its research has centered on novel anti-infective medicines and diseases affecting underserved patient populations.

The company’s lead investigational product has been epetraborole, an oral therapy studied for pulmonary disease caused by Mycobacterium avium complex, a difficult-to-treat bacterial infection.